recurrent epithelial ovarian cancer
Conditions
Interventions
Empirical treatment group:treat according to NCCN Clinical Practice Guidelines for ovarian cancer
treatment according to analyis of sequencing for tumor genomic profiling:Blood and tissue samples collected from the primary surgery are analyzed via sequencing for tumor genomic profiling. Choose opt
Sponsors
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Female patients over 18 years of age; 2) Patients should have received optimal cytoreductive surgery with residual tumor =1.5*10^9/L Platelet count >=100 *10^9/L, ALT (SGPT) <=2-fold of the upper limit of normal, ULN Bilirubin <1.5-fold of the upper limit of normal, Creatinine <1.6 mg/dl; with a normal ejection fraction; 8) Ability andwillingness to give written informed consent.
Exclusion criteria
Exclusion criteria: 1) Non epithelial tumor or borderline tumor; 2) No recurrence patients of postoperative chemotherapy or was performed cytoreductive surgery after chemotherapy ; 3) Second kinds of tumors or other tumors received surgical treatment, the treatment and the surgical treatment will affect the treatment of recurrent ovarian cancer, or affect the prognosis of the patients; 4) The patient has received non platinum chemotherapy treatment 5) To carry out palliative surgical treatment only; 6) The combined disease is not suitable for surgery and / or chemotherapy; 7) Has been treated with radiotherapy, experimental therapy, hormone therapy, chemotherapy or biological agents; 8) Any drug known to have a severe allergic history will be used in clinical trials; 9) Past medical history showed that there were serious complications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Objective Response Rate; | — |
Countries
China
Contacts
Public ContactWen Di
Outcome results
None listed